SEARCH

SEARCH BY CITATION

References

  • 1
    Atkins E. The pathogenesis of fever. Physiol Rev 1960; 40:580646.
  • 2
    Dinarello CA. Biology of interleukin 1: Federation of American Societies for Experimental Biology. Biology 1988; 2:108115.
  • 3
    Lomedico PT, Gubler CP, Hellman CP, et al. Cloning and expression of murine interleukin 1 cDNA in Eschericha coli. Nature 1984; 312:458462.
  • 4
    Dower SK, Kronheim SR, March CJ, et al. The cell surface receptors for interleukin 1 alpha and interleukin 1 beta are identical. Nature 1986; 324:266269.
  • 5
    Nakamura S, Kashimoto S, Kajikawa F, et al. Combination effect of recombinant human interleukin 1α with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991; 51:215221.
  • 6
    Onozaki K, Matsushima K, Aggarwal BB, et al. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135:39623968.
  • 7
    Crump WL III, Owen-Schaub LB, Grimm EA. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine activated killer cells. Cancer Res 1989; 49:149153.
  • 8
    Herman J, Dinarello CA, Kew MC, et al. The role of interleukin 1 (IL-1) in tumor NK cell interactions. Correction of defective NK cell activity in cancer patients by treating target cells with IL-1. J Immunol 1985; 135:28822886.
  • 9
    Yamashita U, Shirakawa F. Restoration of impaired T cell functions in tumor-bearing mice by the administration of interleukin 1. Gann 1987; 78:270278.
  • 10
    Neville ME. Antitumor effects of interleukin 1β: inhibition of angiogenesis. Proc Annu Meet Assoc Cancer Res 1990; 31:1741a.
  • 11
    Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin 1. Nature 1986; 323:8689.
  • 12
    Nakai S, Hirai Y. The therapeutic potential of interleukin 1 beta in the treatment of chemotherapy or radiation induced myelosuppression and in tumor therapy. Biotherapy 1989; 1:339354.
  • 13
    Neta R, Douches S, Oppenheim J. Interleukin 1 is a radioprotector. J Immunol 1987; 136:24832488.
  • 14
    Laver J, Abboude M, Gasparetto C, et al. Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemotherapy. Biotherapy 1989; 1:293300.
  • 15
    Ozaki Y, Ohashi T, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin 1α. Infect Immun 1987; 55:14361440.
  • 16
    Smith JW II, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin 1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10:11411152.
  • 17
    Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin 1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78:14201427.
  • 18
    Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:11621172.
  • 19
    Smith JW II, Urba WJ, Steis R, et al. Phase II trial of interleukin 1 alpha (IL-1α) in combination with indomethacin (IND) in melanoma patients (pts). Proc ASCO 1991; 10:705a.
  • 20
    Steis R, Smith JW II, Janik J, et al. Phase I study of recombinant IL-1 beta (Syntex). Proc ASCO 1991; 10:211a.
  • 21
    Dennis D, Chachoua S, Caron D, et al. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies. Proc ASCO 1992; 11:830a.
  • 22
    Kanz L, Birken R, Brugger W, et al. Biological activities of subcutaneous (s.c.) rhIL-1β in cancer patients. Blood 1992; 80:357a.
  • 23
    Janik JE, Smith JW III, Urba WJ, et al. Phase I trial of intratumoral interleukin 1 alpha (IL-1α). “Melanoma and Biology of the Neural Crest.” Keystone Symposia, Taos, NM, 1992.
  • 24
    Lestingi TM, Vogelzang NJ, Richards JM, et al. Phase I trial of recombinant interleukin 1α (IL-1) and recombinant interleukin 2 (IL-2). Proc ASCO 1993; 12:976a.
  • 25
    Triozzi PL, Kim JA, Martin EW, et al. Phase I trial of escalating doses of Interleukin 1β in combination with a fixed dose of Interleukin 2. J Clin Oncol 1995; 13:482489.
  • 26
    Starnes HF, Hartman G, Torti F, et al. Recombinant human interleukin 1β (IL-1β) has anti-tumor activity and acceptable toxicity in metastatic malignant melanoma. Proc ASCO 1991; 10:292a.
  • 27
    Janik JE, Miller LL, Longo DL, et al. Phase II trial of Interleukin 1α and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996; 88:4449.
  • 28
    Redman BG, Abubaker YC, Chou T, et al. Phase II trial of recombinant interleukin 1β in patients with metastatic renal cell carcinoma. J Immunother 1994; 16:211215.
  • 29
    Fibbe WE, van Damme J, Billiau A, et al. Interleukin 1 induces human marrow stromal cells in long-term culture to produce granulocyte colony-stimulating factor and macrophagecolony-stimulating factor. Blood 1988; 71:430435.
  • 30
    Tosato G, Jones KD. Interleukin 1 induces interleukin 6 production in peripheral blood monocytes. Blood 1990; 75:13051310.
  • 31
    Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators (Review: Stratton Lecture 1990). Blood 1991; 78:119.
  • 32
    Dubois CM, Ruscetti FW, Keller JR, et al. In vivo interleukin 1 (IL-1) administration indirectly promotes type II IL-1 receptor expression on hematopoietic bone marrow cells: novel mechanism for the hematopoietic effects of IL-1. Blood 1991; 78:28412847.
  • 33
    Castelli MP, Black PL, Schneider M, et al. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140:38303837.
  • 34
    Futami H, Jansen R, MacPhee MJ, et al. Chemoprotective effects of recombinant human IL-1α in cyclophosphamide-treated normal and tumor-bearing mice. J Immunol 1990; 145: 41214130.
  • 35
    Smith JW II, Longo DL, Alvord WG, et al. The effects of treatment with interleukin 1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328:756761.
  • 36
    Vadhan-Raj S, Kudelka A, Garrison L, et al. Effects of interleukin 1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12:707714.
  • 37
    Schuchter L, Neuberg D, Atkins M, et al. A phase I study of interleukin 1 alpha and high-dose cyclophosphamide in patients with advanced cancer. Proc ASCO 1994; 13:133a.
  • 38
    Bookman MA, Caron DA, Hogan WM, et al. Phase-1 evaluation of dose-intense chemotherapy with interleukin 1α (IL-1α) for gynecologic malignancies. Proc ASCO 1993; 12:868a.
  • 39
    Wheeler RH, Meredith RF, Saleh MN, et al. A phase II trial of IL-1 plus radioimmunotherapy (RIT) in patients with metastatic colon cancer. Proc ASCO 1994; 13:295a.
  • 40
    Wilson WH, Bryant G, Jain V, et al. Phase I study of infusional interleukin 1α (IL-1) with ifosfamide (I), CBDCA (C), and etoposide (E) (ICE) and autologous bone marrow transplant (BMT). Proc Am Soc Clin Oncol 1992; 11:335a.
  • 41
    Wilson WH, Bryant G, Fox M, et al. Interleukin 1α administered before high-dose isosfamide (I), CBDCA (C), and etoposide (E) (ICE) with autologous bone marrow rescue shortens neutrophil recovery: a phase I/II study. Proc ASCO 1993; 12:937a.
  • 42
    Vredenburgh J, Ross M, Kurtzberg J, et al. Phase I trial of interleukin 1β (IL-1β) following high-dose chemotherapy and autologous bone marrow transplantation (ABMT). Blood 1991; 78:6a.
  • 43
    Weisdorf DJ, Katsanis E, Verfaillie C, et al. Interleukin 1α after autologous transplantation for lymphoma/Hodgkin's disease: clinical and hematologic effects. Blood 1992; 80:1321a.
  • 44
    Weisdorf D, Katsanis E, Verfaillie C, et al. Interleukin 1α administered after autologous transplantation: phase I/II clinical trial. Blood 1994; 84:20442049.
  • 45
    Nemunaitis J, Buckner CD, Press O, et al. Phase I trial with interleukin 1β (IL-1β) in patients undergoing autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML). Blood 1991; 78:8a.
  • 46
    Nemunaitis J, Applebaum FR, Lilleby K, et al. Phase I study with recombinant human interleukin 1β in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 1994; 83:34733479.
  • 47
    Beasley D, Schwartz JH, Brenner BM. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87:602608.
  • 48
    Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87:36293632.
  • 49
    Kilbourn RG, Gross SS, Lodato JA, et al. Inhibition of interleukin 1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin 1-alpha-induced hypotension by N-omega-amino-L-arginine. J Natl Cancer Inst 1992; 84:10081016.
  • 50
    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164170.
  • 51
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:17731778.
  • 52
    Bruno E, Hoffman R. Effect of interleukin 6 on in vitro human megakaryocytopoiesis: its interaction with other cytokines. Exp Hematol 1989; 17:10381041.
  • 53
    Briddell RA, Brandt JE, Leemhuis TB, et al. Role of cytokines in sustaining long-term human megakaryocytopoiesis in vitro. Blood 1994; 79:332337.
  • 54
    Ikebuchi K, Ihle JN, Hirai Y, et al. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin 1, interleukin 6, and granulocyte-colony stimulating factor. Blood 1988; 72:20072014.
  • 55
    Hornung RL, Longo DL. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 1992; 80:7783.
  • 56
    Gordon MS, Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992; 80:302307.
  • 57
    Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369(6481):565568.
  • 58
    Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369(6481):568571.